Ask AI
ProCE Banner Activity

PROMISE-US: Phase IV Noninterventional Registry Study Evaluating Long-term Efficacy/Durability of Ibalizumab + Other ARVs in People Living With MDR HIV

Conference Coverage
Slideset

In the first interim analysis from this study, people treated with ibalizumab-containing ART demonstrated comparable viral suppression and immunologic recovery rates vs people receiving regimens without ibalizumab, despite having baseline clinical indicators of more advanced HIV disease.

Released: March 03, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by independent educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Target Audience

This activity is intended for physicians, pharmacists, registered nurses, and other healthcare professionals who care for people living with or at risk of HIV infection.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Appropriately apply and counsel patients regarding the clinical role(s) of new and investigational ART regimens and strategies

  • Devise HIV management strategies based on the results of recent clinical studies of established antiretroviral agents

  • Integrate the latest scientific findings to develop and optimize effective HIV prevention interventions